Cargando…

Effect of PARP Inhibitor Combined with Bevacizumab on Platinum-Resistant Recurrent Ovarian Epithelial Carcinoma

OBJECTIVE: This study was aimed at investigating the efficacy of PARP inhibitor combined with bevacizumab in the treatment of platinum-resistant recurrent ovarian epithelial carcinoma. METHODS: A total of 84 patients with platinum-resistant recurrent ovarian epithelial carcinoma treated in our hospi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Li, Liu, Caixia, Li, Yun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9205723/ https://www.ncbi.nlm.nih.gov/pubmed/35720032 http://dx.doi.org/10.1155/2022/4600145

Ejemplares similares

Retracted: Effect of PARP Inhibitor Combined with Bevacizumab on Platinum-Resistant Recurrent Ovarian Epithelial Carcinoma
por: Methods in Medicine, Computational and Mathematical
Publicado: (2023)

Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis
por: Bartoletti, Michele, et al.
Publicado: (2020)

Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models
por: Kim, Hyoung, et al.
Publicado: (2020)

Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer
por: McMullen, Michelle, et al.
Publicado: (2020)

Surgery in platinum-resistant recurrent epithelial ovarian carcinoma
por: Zhao, Ling-Qin, et al.
Publicado: (2022)

Ovarian cancer recurrence: “is the definition of platinum resistance modified by PARP inhibitors and other intervening treatments?”
por: Pejovic, Tanja, et al.
Publicado: (2022)

The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancer
por: Barber, Emma L., et al.
Publicado: (2013)

Economic Evaluation of Bevacizumab for Treatment of Platinum-Resistant Recurrent Ovarian Cancer in Canada
por: Ball, Graeme, et al.
Publicado: (2017)

An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer
por: Xu, Jing, et al.
Publicado: (2022)

Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer
por: Della Pepa, Chiara, et al.
Publicado: (2014)

PARP Inhibitor in Platinum-Resistant Ovarian Cancer: Single-Center Real-World Experience
por: Agarwal, Amit, et al.
Publicado: (2021)

Bevacizumab combined with chemotherapy in platinum-resistant ovarian cancer: beyond the AURELIA trial
por: Lyon, Kristopher A., et al.
Publicado: (2020)

PARP inhibitors in ovarian cancer: overcoming resistance with combination strategies
por: Miller, Rowan E, et al.
Publicado: (2022)

A phase II study of the combination chemotherapy of bevacizumab and gemcitabine in women with platinum-resistant recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer
por: Nagao, Shoji, et al.
Publicado: (2020)

Interstitial brachytherapy combined with PARP inhibitors in the treatment of chemoresistant recurrent epithelial ovarian cancer: A case report
por: Bian, Yuan, et al.
Publicado: (2022)

PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
por: Morgan, Robert D., et al.
Publicado: (2018)

Low-dose-intensity bevacizumab with weekly irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer
por: Liu, Ying, et al.
Publicado: (2015)

Can HIPEC be used against platinum-resistance and for inducing sensitivity to PARP inhibitors in ovarian cancer?
por: Batista, Thales Paulo, et al.
Publicado: (2020)

Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer [Corrigendum]
Publicado: (2014)

REBECA trial: a new piece of the evidence for bevacizumab in platinum-resistant recurrent ovarian cancer
por: Lavacchi, Daniele, et al.
Publicado: (2020)

Bevacizumab and oral metronomic cyclophosphamide in platinum-resistant ovarian cancer
por: Pujade-Lauraine, Eric
Publicado: (2013)

Overcoming resistance to PARP inhibitor in epithelial ovarian cancer, are we ready?
por: Ray-Coquard, Isabelle, et al.
Publicado: (2020)

Observation of the therapeutic effect of apatinib in advanced platinum-resistant recurrent epithelial ovarian cancer
por: Pan, Zhongmian, et al.
Publicado: (2023)

High Expression of PARP1 in Tumor and Stroma Cells Predicts Different Prognosis and Platinum Resistance in Patients With Advanced Epithelial Ovarian Cancer
por: Zuo, Wei-Wei, et al.
Publicado: (2022)

Corrigendum: High expression of PARP1 in tumor and stroma cells predicts prognosis and platinum resistance in patients with advanced epithelial ovarian cancer
por: Zuo, Wei-Wei, et al.
Publicado: (2023)

Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives
por: McClung, E Clair, et al.
Publicado: (2016)

Anlotinib combined with etoposide for platinum-resistant recurrent ovarian cancer: A case report
por: Sun, Li, et al.
Publicado: (2020)

The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer
por: Sekine, Masayuki, et al.
Publicado: (2021)

Layer‐by‐layer nanoparticles for novel delivery of cisplatin and PARP inhibitors for platinum‐based drug resistance therapy in ovarian cancer
por: Mensah, Lawrence B., et al.
Publicado: (2019)

Onvansertib and paclitaxel combined in platinum-resistant ovarian carcinomas
por: Affatato, Roberta, et al.
Publicado: (2022)

Comparative Efficacy and Safety of PARP Inhibitors as Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis
por: Xu, Yangchun, et al.
Publicado: (2021)

Comparison of the Efficacy and Safety of PARP Inhibitors as a Monotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis
por: Wang, Hongmei, et al.
Publicado: (2021)

Perspectives on PARP Inhibitor Combinations for Ovarian Cancer
por: Bonadio, Renata Colombo, et al.
Publicado: (2021)

The Emerging Role of PARP Inhibitors in the Treatment of Epithelial Ovarian Cancer
por: Gien, Lilian T., et al.
Publicado: (2010)

Correction to: The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer
por: Sekine, Masayuki, et al.
Publicado: (2021)

ATR Inhibitors in Platinum-Resistant Ovarian Cancer
por: Li, Siyu, et al.
Publicado: (2022)

Potential efficacy of weekly low-dose administration of bevacizumab as a combination therapy for platinum-resistant ovarian carcinoma: a retrospective analysis
por: Suminokura, Jin, et al.
Publicado: (2022)

Real-World Efficacy of Bevacizumab in Patients With Recurrent Epithelial Ovarian Cancer
por: Hung, Jo-Ni, et al.
Publicado: (2022)

Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer
por: Lin, Z. Ping, et al.
Publicado: (2018)

Combined inhibition of BADSer99 phosphorylation and PARP ablates models of recurrent ovarian carcinoma
por: Zhang, Xi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_39nq6b13590b2ng0oeairjtra6